Alphabet Corporation founded Isomorphic Laboratories, which uses artificial intelligence to discover new types of drugs. It was led by the general director of the DeepMind laboratory, Demis Hassabis.
Thrilled to announce the launch of a new Alphabet company @IsomorphicLabs… Our mission is to reimagine the drug discovery process from first principles with an AI-first approach, to accelerate biomedical breakthroughs and find cures for diseases. Details: https://t.co/WQrG36ddgZ pic.twitter.com/RRV6VeDhpL
– Demis Hassabis (@demishassabis) November 4, 2021
Their goal, Hassabis says, is to “rethink” the drug development process using an AI-first approach:
“We believe that fundamental use of advanced computational and artificial intelligence techniques will help scientists take their work to the next level and significantly accelerate the drug discovery process.”
Isomorphic will build models that can predict drug interactions with the body. The lab is leveraging DeepMind’s developments, including the AlphaFold 2 AI protein folding prediction tool.
At the same time, both laboratories will remain independent and will cooperate from time to time.
Hassabis added that the company has no plans to develop its own drugs. Instead, she will focus on developing partnerships with pharmaceutical companies and selling her models.
Earlier, DeepMind opened access to a database of human protein structures created by the AlphaFold neural network.
Recall that in September, scientists developed an algorithm to identify viruses that can pass from animals to humans.
In March, NVIDIA developed artificial intelligence that accelerates analysis of the human genome.
